ADOCIA overview

Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment...

Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30 th , 2023 : Number of shares : 9,988 Cash balance of the liquidity account: 208,714.02 During the 1 st half of 2023, a total of: Buy side 102,076 shares € 356,569.03 540 transactions Sell side 121,058 shares € 435,436.25 573 transactions The following resources appeared on the last half year statement on December...

Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the “ Company ”), announces today the availability of an amendment to its 2022 Universal Registration Document, filed by the Company with the Autorité des Marchés Financiers (" AMF ") on July 26, 2023, under number D.23-0346-A01, and an admission Prospectus approved...

Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases (the “ Company ”), announced today its financial results for the second quarter of 2023, as well as the completion of a €10 million financing operation as announced in a press release on July 5, 2023. " First and foremost, I would like to...

Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, confirms its eligibility for the “PEA – PME” stock savings tax regime, which decree has been published in the French Journal Officiel on March 4, 2014 (Decree n ° 2014-283), and which entered into force on March 6, 2014. To be eligible...

Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovative formulations...

Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it has signed an exclusivity agreement with Sanofi for M1Pram. The payment of 10 million euros to Adocia gives Sanofi the exclusive right to negotiate a worldwide partnership for the product. Payment of this sum is due to take place in the next few...